Amgen and Eli Lilly to collaborate on potential COVID-19 therapies

THOUSAND OAKS, Calif. – Amgen Inc. and Eli Lilly and Co. on Thursday announced a global antibody manufacturing collaboration that would increase supply capacity available for Lilly's potential COVID-19 therapies, should any of them prove successful in clinical testing and receive regulatory approval. Lilly said that it is studying several potential neutralizing antibodies for the…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.